Utility of prophylactic antibiotics for preventing febrile neutropenia during cabazitaxel therapy for castration-resistant prostate cancer

Abstract The aim was to investigate the efficacy of prophylactic antibiotics for the prevention of febrile neutropenia (FN) during cabazitaxel therapy for castration-resistant prostate cancer (CRPC) with G-CSF. We retrospectively studied 443 cycles of cabazitaxel therapy given to 56 patients with CR...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Keitaro Watanabe, Takeo Kosaka, Hiroshi Hongo, Mototsugu Oya
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/7a1f5d7236ac4d8599650ce4d896c313
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:7a1f5d7236ac4d8599650ce4d896c313
record_format	dspace
spelling	oai:doaj.org-article:7a1f5d7236ac4d8599650ce4d896c3132021-12-02T15:51:11ZUtility of prophylactic antibiotics for preventing febrile neutropenia during cabazitaxel therapy for castration-resistant prostate cancer10.1038/s41598-021-87758-y2045-2322https://doaj.org/article/7a1f5d7236ac4d8599650ce4d896c3132021-04-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-87758-yhttps://doaj.org/toc/2045-2322Abstract The aim was to investigate the efficacy of prophylactic antibiotics for the prevention of febrile neutropenia (FN) during cabazitaxel therapy for castration-resistant prostate cancer (CRPC) with G-CSF. We retrospectively studied 443 cycles of cabazitaxel therapy given to 56 patients with CRPC at Keio University Hospital between May 2012 and August 2018. Statistical analysis was conducted to determine whether the combination of prophylactic G-CSF and antibiotics was more effective in preventing FN, compared with prophylactic G-CSF alone. Prophylactic PEG-G-CSF or G-CSF was administered in all 443 cycles. Only fluoroquinolones were used as prophylactic antibiotics and were administered in 328 cycles (74.0%). FN occurred in 5 cycles (1.1%). Prophylactic antibiotics were administered in 327 cycles (74.6%) in the FN-negative group and in only 1 cycle (20.0%) in the FN-positive group. Chi-square test indicated the incidence of FN was significantly lower in the group that received prophylactic antibiotics compared with the group that did not receive prophylactic antibiotics (P = 0.017). Compared with prophylactic G-CSF alone, prophylactic G-CSF and antibiotics significantly suppressed the occurrence of FN.Keitaro WatanabeTakeo KosakaHiroshi HongoMototsugu OyaNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-7 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Keitaro Watanabe Takeo Kosaka Hiroshi Hongo Mototsugu Oya Utility of prophylactic antibiotics for preventing febrile neutropenia during cabazitaxel therapy for castration-resistant prostate cancer
description	Abstract The aim was to investigate the efficacy of prophylactic antibiotics for the prevention of febrile neutropenia (FN) during cabazitaxel therapy for castration-resistant prostate cancer (CRPC) with G-CSF. We retrospectively studied 443 cycles of cabazitaxel therapy given to 56 patients with CRPC at Keio University Hospital between May 2012 and August 2018. Statistical analysis was conducted to determine whether the combination of prophylactic G-CSF and antibiotics was more effective in preventing FN, compared with prophylactic G-CSF alone. Prophylactic PEG-G-CSF or G-CSF was administered in all 443 cycles. Only fluoroquinolones were used as prophylactic antibiotics and were administered in 328 cycles (74.0%). FN occurred in 5 cycles (1.1%). Prophylactic antibiotics were administered in 327 cycles (74.6%) in the FN-negative group and in only 1 cycle (20.0%) in the FN-positive group. Chi-square test indicated the incidence of FN was significantly lower in the group that received prophylactic antibiotics compared with the group that did not receive prophylactic antibiotics (P = 0.017). Compared with prophylactic G-CSF alone, prophylactic G-CSF and antibiotics significantly suppressed the occurrence of FN.
format	article
author	Keitaro Watanabe Takeo Kosaka Hiroshi Hongo Mototsugu Oya
author_facet	Keitaro Watanabe Takeo Kosaka Hiroshi Hongo Mototsugu Oya
author_sort	Keitaro Watanabe
title	Utility of prophylactic antibiotics for preventing febrile neutropenia during cabazitaxel therapy for castration-resistant prostate cancer
title_short	Utility of prophylactic antibiotics for preventing febrile neutropenia during cabazitaxel therapy for castration-resistant prostate cancer
title_full	Utility of prophylactic antibiotics for preventing febrile neutropenia during cabazitaxel therapy for castration-resistant prostate cancer
title_fullStr	Utility of prophylactic antibiotics for preventing febrile neutropenia during cabazitaxel therapy for castration-resistant prostate cancer
title_full_unstemmed	Utility of prophylactic antibiotics for preventing febrile neutropenia during cabazitaxel therapy for castration-resistant prostate cancer
title_sort	utility of prophylactic antibiotics for preventing febrile neutropenia during cabazitaxel therapy for castration-resistant prostate cancer
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/7a1f5d7236ac4d8599650ce4d896c313
work_keys_str_mv	AT keitarowatanabe utilityofprophylacticantibioticsforpreventingfebrileneutropeniaduringcabazitaxeltherapyforcastrationresistantprostatecancer AT takeokosaka utilityofprophylacticantibioticsforpreventingfebrileneutropeniaduringcabazitaxeltherapyforcastrationresistantprostatecancer AT hiroshihongo utilityofprophylacticantibioticsforpreventingfebrileneutropeniaduringcabazitaxeltherapyforcastrationresistantprostatecancer AT mototsuguoya utilityofprophylacticantibioticsforpreventingfebrileneutropeniaduringcabazitaxeltherapyforcastrationresistantprostatecancer
_version_	1718385641029369856

Utility of prophylactic antibiotics for preventing febrile neutropenia during cabazitaxel therapy for castration-resistant prostate cancer

Ejemplares similares